[Pharm-policy] Ivax Paclitaxel approval in EU for Karposi Sarcoma

[James Love]

But AFAIK, this approval is limited to use for Karposi Sarcoma.
Jamie


http://www.ivax.com/ComNewsv2.htm


    MIAMI--(BUSINESS WIRE)--July 21, 1999--IVAX Corporation (AMEX:IVX)
today announced that on July
19, the European Commission signed the Decision to grant a Marketing
Authorization for its proprietary anti-cancer drug, PAXENE(R)
(paclitaxel), in the 15 member-states of the European Union, for the
treatment of AIDS-related Kaposi's sarcoma in patients who have failed
prior liposomal anthracycline therapy. PAXENE(R) was developed by Baker
Norton Pharmaceuticals, IVAX's U.S.-based proprietary research and
development subsidiary; this European approval will be held by Norton
Healthcare Limited, the company's subsidiary in the United Kingdom.



-- 
James Love  mailto:love@cptech.org http://www.cptech.org
Consumer Project on Technology, P.O. Box 19367, Washington, DC 20036
voice 1.202.387.8030  fax  1.202.234.5176